ReviewCurrent opinion in rheumatology2016
Update on cardiovascular disease in lupus.
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus.JCI insight · 2018Trial
- The integrative role of the microbiome in systemic immuno-inflammatory aberrations.Folia microbiologica · 2026Review
- The ERβ Agonist, OSU-ERβ-012, Mitigates Inflammation in a Chimeric Model of Systemic Lupus Erythematosus.ACR open rheumatology · 2026Article
- Observational
- A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis.Rheumatology international · 2025Review
- Macrophages Unmasked: Their Pivotal Role in Driving Atherosclerosis in Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2025Review
- Regulatory B Cells Evaluation in Systemic Lupus Erythematosus Patients with Subclinical Atherosclerosis and Secondary Antiphospholipid Syndrome.Mediterranean journal of rheumatology · 2023Article
- Review
- Review
- Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study.World journal of gastroenterology · 2021Article
- Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?International journal of molecular sciences · 2021Review
- Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis.Biomedicines · 2020Review
- Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.American journal of physiology. Renal physiology · 2020Article
- Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study.Lipids in health and disease · 2020Article
- Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases.Oxidative medicine and cellular longevity · 2020Review
- Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous.Pediatric rheumatology online journal · 2019Article
- Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus.Current rheumatology reports · 2019Review
- Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients.International journal of molecular sciences · 2019Article
- Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study.Annals of internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewAtherosclerotic cardiovascular disease confers significant morbidity and mortality in patients with systemic lupus erythematosus (SLE) and cannot be fully explained by traditional cardiovascular risk factors. Recent immunologic discoveries have outlined putative pathways in SLE that may also accelerate the development of atherosclerosis. RECENT
findingsAberrant innate and adaptive immune responses implicated in lupus pathogenesis may also contribute to the development of accelerated atherosclerosis in these patients. Defective apoptosis, abnormal lipoprotein function, autoantibodies, aberrant neutrophil responses, and a dysregulated type I interferon pathway likely contribute to endothelial dysfunction. SLE macrophages have an inflammatory phenotype that may drive progression of plaque. SUMMARY: Recent discoveries have placed increased emphasis on the immunology of atherosclerotic cardiovascular disease. Understanding the factors that drive the increased risk for cardiovascular disease in SLE patients may provide selective therapeutic targets for reducing inflammation and improving outcomes in atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.